Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 10/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | GUCY1A1 | Q02108 | 18/20 | 0.49 |
| ▸ | GUCY1B1 | Q02153 | 18/20 | 0.49 |
| ▸ | GUCY1B2 | O75343 | 5/20 | 0.42 |
| ▸ | GUCY1A2 | P33402 | 5/20 | 0.42 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.40 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.40 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3437467 | 0.90 | KCNH2 (0.61) | KCNH2ADORA3GUCY1A1GUCY1B1GUCY1B2 | |
| SCHEMBL19513351 | 0.89 | KCNH2 (0.43) | KCNH2ADORA3GUCY1A1GUCY1B1GUCY1B2 | |
| SCHEMBL3437390 | 0.85 | GUCY1A1 (0.43) | KCNH2ADORA3GUCY1A1GUCY1B1GUCY1B2 | |
| SCHEMBL3437446 | 0.84 | KCNH2 (0.65) | KCNH2ADORA3GUCY1A1GUCY1B1GUCY1B2 | |
| SCHEMBL16081967 | 0.83 | GUCY1B2 (0.63) | KCNH2ADORA3GUCY1A1GUCY1B1GUCY1B2 | |
| SCHEMBL10323526 | 0.82 | KCNH2 (0.59) | KCNH2ADORA3GUCY1A1GUCY1B1GUCY1B2 | |
| SCHEMBL3437516 | 0.81 | KCNH2 (0.49) | KCNH2ADORA3GUCY1A1GUCY1B1GUCY1B2 | |
| SCHEMBL21565179 | 0.80 | GUCY1B2 (0.43) | KCNH2ADORA3GUCY1A1GUCY1B1GUCY1B2 | |
| SCHEMBL19513159 | 0.79 | KCNH2 (0.47) | KCNH2ADORA3GUCY1A1GUCY1B1GUCY1B2 | |
| SCHEMBL18404829 | 0.76 | KCNH2 (0.54) | KCNH2ADORA3GUCY1A1GUCY1B1GUCY1B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190345130-A1 | SGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2019-11-14 | — | — | US | disclosed |
| US-10189809-B2 | SGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170305878-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170305878-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-10-26 | — | — | US | disclosed |
| EP-3173407-A1 | SGC STIMULATORS | Ironwood Pharmaceuticals, Inc. (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2588465-B1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS INC (US) | 2017-01-25 | — | — | EP | disclosed |
| US-20140323448-A1 | sGC STIMULATORS | Ironwood Pharmaceuticals Inc. (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140323448-A1 | sGC STIMULATORS | Ironwood Pharmaceuticals Inc. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8748442-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748442-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120184516-A1 | sGC Stimulators | CYCLERION THERAPEUTICS, INC. | 2012-07-19 | — | — | US | disclosed |
| WO-2012003405-A1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323448-A1 | sGC STIMULATORS | GUCY1A1, PTGIS, GUCY1B1 | KCNH2 2088/4885ADORA3 2877/4885GUCY1A1 1/4885 |
| US-20120184516-A1 | sGC Stimulators | GUCY1A1, PTGIS, GUCY1B1 | KCNH2 2088/4885ADORA3 2877/4885GUCY1A1 1/4885 |
| US-20170305878-A1 | sGC STIMULATORS | GUCY1A1, PTGIS, GUCY1B1 | KCNH2 2088/4885ADORA3 2877/4885GUCY1A1 1/4885 |
| US-10189809-B2 | SGC stimulators | GUCY1A1, PTGIS, GUCY1B1 | KCNH2 2088/4885ADORA3 2877/4885GUCY1A1 1/4885 |
| US-20190345130-A1 | SGC STIMULATORS | GUCY1A1, PTGIS, GUCY1B1 | KCNH2 2088/4885ADORA3 2877/4885GUCY1A1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.